ARID1A and colorectal carcinoma: Along with the previous in vivo study that revealed the role of ARID1A mutations in the increased mutational load and antitumor effects of ICIs,11 using clinically obtained specimens, this study reinforced the idea that ARID1A mutations can be biomarkers for using ICIs in CRC patients.